Skip to main content

Table 2 Risk factors for overall survival in stage IB NSCLC

From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

  Univariate analysis Multivariate analysis (Cox hazard model)
  HR (95% CI) p value HR (95% CI) p value
Age 1.053 (1.015-1.094) 0.006 1.031 (0.995-1.069) 0.092
Sex (female vs. male) 0.571 (0.254-1.284) 0.175 0.689 (0.300-1.584) 0.381
ECOG    1 (vs. 0) 2.343 (1.128-4.864) 0.022 1.717 (0.804-3.668) 0.163
       2 (vs. 0) 0 0.976 0 0.977
Pneumonectomy 1.389 (0.421-4.585) 0.590
Tumor size 0.980 (0.947-1.015) 0.264
Numbers of dissected lymph nodes 0.987 (0.956-1.018) 0.408
Adenocarcinoma (vs. non-adenocarcinoma) 0.898 (0.437-1.845) 0.769
Differentiation (moderate to poor vs. well) 1.317 (0.638-2.944) 0.419
Lymphovascular invasion 0.494 (0.115-2.110) 0.341
Pleural invasion (pl2 and pl1 vs. pl0) 1.228 (0.524-2.875) 0.637
Platinum based chemotherapy (vs. no adjuvant therapy) 0.360 (0.159-0.813) 0.014 0.428 (0.184-0.998) 0.049